Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. - Wikidata - wikimedia - TriplyDB

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

http://www.wikidata.org/entity/Q35030581

about

Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic Syndrome Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.Rituximab for nephrotic syndrome in children.The efficacy of rituximab in adult frequently relapsing minimal change disease.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis Rituximab Treatment for Nephrotic Syndrome in Children A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.Rituximab in children with resistant idiopathic nephrotic syndrome.Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.IgM contributes to glomerular injury in FSGS Antibody therapy of pediatric B-cell lymphoma Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome Rituximab in idiopathic nephrotic syndrome: does it make sense?Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review.Rituximab in immunologic glomerular diseases.Childhood nephrotic syndrome--current and future therapies.Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.Rituximab therapy in nephrotic syndrome: implications for patients' management.Is rituximab effective in childhood nephrotic syndrome? Yes and no.B-cell-targeted therapy in adult glomerulonephritis.Biologic agents in the treatment of glomerulonephritides.Regulatory T cells and minimal change nephropathy: in the midst of a complex network.Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.How randomised trials have improved the care of children with kidney disease.Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.Nephrotic syndrome in infants and children: pathophysiology and management.Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.

P2860

Q24202861-6231F3A3-2CB6-4A52-BFA1-81F751F5713D Q26864297-86336FEB-F02D-4394-B658-4299D6A3DCED Q28548569-7EFB96CF-5985-4F7B-BCDC-02D51697751A Q30240107-03C529C4-C340-40A9-8454-496384ADC11E Q30844502-C096C679-7B95-4BE9-8AFD-82A951D9FA22 Q33555088-C367B89C-AC5C-41CD-B329-69CF98A26809 Q33793403-862C9973-3518-4971-9AD3-DA853FC7FD84 Q35040896-B19F13F2-8034-4B37-87EF-CF7584D55DE5 Q35113681-2B1A959D-79E3-4EC7-957C-9E69D7F7ABDF Q35674857-59D51DAC-DA48-4089-AC2B-1A29D558693F Q35982341-1B255079-C671-4590-AE7D-02A89EED437C Q36003160-13FC4BDE-2654-4B13-8FA7-7524722A446E Q36151665-C87BD886-8030-4674-8C02-A15455BFC53F Q36638347-7A709764-1415-4F5B-91DD-82CD20512247 Q36732959-442511F4-E681-436C-B403-1201E6CDD293 Q36770915-18550107-894C-4273-BC36-13B7FA426CC8 Q37108328-18A791FD-F999-4EBD-9C00-378426A5E7CC Q37275486-BA29BAE2-8F64-4297-A58E-82A69CABE817 Q37375752-4B2F998E-DA6A-42B6-AF6F-206247EB56D5 Q37670299-5B5363EB-8551-42E0-B538-B488C6721A92 Q37728395-00768520-BBED-4160-8AFF-C9679FB2F7DA Q37969115-7F874DC3-BB7E-4F55-8AE9-4A9D14FA317D Q37989298-5F5A1710-6EAA-434B-980C-F8800C4FC788 Q38017937-46FD02F3-B44E-46E3-B893-99A67320C182 Q38050961-72216343-BC83-4DB3-A32B-ABF6AD8E1269 Q38075787-9700D2C9-4974-4D27-A4A3-CC6F50B62BA1 Q38118894-BF766FA6-221D-4BF8-BCD9-D45E40872563 Q38159787-66A3A03B-A28C-4CB6-87AB-3C5F7D7896D7 Q38514894-2C1E4821-F897-481E-8AAF-ECED3CB87AC0 Q38543132-2862203F-9A22-447A-8C69-4AB636D4CC51 Q38622603-3F22C138-F2BE-4398-BA7B-1FFBC5D90B7F Q38679589-1312F85E-B8A7-4063-BEC6-F1281638E38A Q38738516-E766E349-68B6-4363-A94B-2DF4884D8293 Q38895019-1D5729FE-9E77-472D-97AF-70160BF8DBE2 Q38896218-4C6C19F2-024A-4D83-87DC-59BF2A22BA92 Q38917590-CFB041CC-E556-47DD-A173-3E782DDE235F Q39440837-DF6087E2-1773-431E-8351-6BFCA269477C Q39456170-BC0D05D5-9739-47DC-85A9-145B3C856252 Q40039238-1DD79E93-ABD6-4958-B007-D67DD9EA8955 Q40572300-0EF643F6-CC19-4F5C-83CA-BD9FDF2A4985

P2860

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

http://www.wikidata.org/entity/Q35030581

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Short-term effects of rituxima ...... a randomized controlled trial.

@ast

Short-term effects of rituxima ...... a randomized controlled trial.

@en

type

label

Short-term effects of rituxima ...... a randomized controlled trial.

@ast

Short-term effects of rituxima ...... a randomized controlled trial.

@en

prefLabel

Short-term effects of rituxima ...... a randomized controlled trial.

@ast

Short-term effects of rituxima ...... a randomized controlled trial.

@en

P1433

Q35030581-316E2AE7-5760-4773-9F1C-EED1ED0500C8

P1476

Q35030581-9712AD91-57AF-4592-91EC-3F821D08505E

P2093

Q35030581-09A07991-D32E-442E-804E-8CA60D58460F

Q35030581-1A0B7488-BCC5-47AA-A2D2-ED5F22881BD5

Q35030581-2701FDF5-9354-41D5-A3D9-00E2410C81FC

Q35030581-783D99C0-E64E-4D83-BF16-08B98E34B30E

Q35030581-7E7D2710-8590-4009-AA7D-DF6740FF2656

Q35030581-9BF25718-826F-4C5E-A2D3-6973CD8897C4

Q35030581-BFD6404C-8017-4F80-8EBC-F08A29952497

Q35030581-E450F0E4-AD5E-4D2F-B56A-E751AF8433FD

Q35030581-E90BC3F2-C491-4973-8466-7575B374AD52

Q35030581-ED15588C-640C-446C-8EE5-9B3BA13D8F54

P2860

Q35030581-26AD7E16-46BE-4593-A297-14A3750866E0

Q35030581-3DB71322-6BB8-417E-987B-AE7C1A7B1AB2

Q35030581-4CA33154-DF48-4676-B9F9-4734C896D3BA

Q35030581-54136262-598D-4EBE-8825-A271EE954B5B

Q35030581-5BEED551-6EDE-4DC7-B4FE-4D9BA4694D0D

Q35030581-68AD7DC2-FA38-4E7A-A5B0-717DC30D6D19

Q35030581-6BB61C10-0F8C-4B18-B2D2-12CE671D0A05

Q35030581-7FE99638-8DC4-42E8-8716-EAEE91788284

Q35030581-82301FE0-CD96-475A-82B4-7EA91A6F17BB

Q35030581-92E4A0B8-CA61-4661-B979-57C2E596692F

P304

Q35030581-D7DBA7EC-435A-4DB1-A201-8CBCCFAC691E

P31

Q35030581-B86B7C3B-B406-4BD9-AB52-D0D5313ED87F

P356

Q35030581-3DD7490D-C4D4-43F5-8B2F-2128296B77CF

P433

Q35030581-164530FD-E7BB-4FEA-B5FD-BB84B9D320B9

P478

Q35030581-C34F33F8-A1A0-4A94-A942-3049FF78CD90

P50

Q35030581-7B3DEFDC-38E4-47E4-8F7B-D28C963C4D36

Q35030581-87B16EB8-4B5C-4A72-BDB0-DF17D58C042C

Q35030581-D1AC4F2A-F02F-4B89-AB98-920A581BCAD0

Q35030581-D87DF35C-D720-4FB7-96B6-C2EFCB6D751F

P577

Q35030581-E3F12023-E236-4D44-9306-7A927A372A6C

P698

Q35030581-F1B047B1-538A-4840-B81B-DBF769412B72

P932

Q35030581-47589F6F-A745-4815-B5A7-838A22D1F83F

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Short-term effects of rituxima ...... a randomized controlled trial.

@en

P2093

Alberto Magnasco

http://www.w3.org/2001/XMLSchema#string

Elisa Benetti

http://www.w3.org/2001/XMLSchema#string

Felice Sica

http://www.w3.org/2001/XMLSchema#string

Floriana Scozzola

http://www.w3.org/2001/XMLSchema#string

Francesco Scolari

http://www.w3.org/2001/XMLSchema#string

Luciana Ghio

http://www.w3.org/2001/XMLSchema#string

Mirco Belingheri

http://www.w3.org/2001/XMLSchema#string

Nadia Dallera

http://www.w3.org/2001/XMLSchema#string

Pietro Ravani

http://www.w3.org/2001/XMLSchema#string

Rossella Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome

Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.

Broadening the spectrum of diseases related to podocin mutations.

Molecular basis of glomerular permselectivity.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Serum creatinine levels are significantly influenced by renal size in the normal pediatric population.

Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.

P304

1308-1315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.09421010

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Gian Marco Ghiggeri

Alberto Edefonti

P577

2011-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21566104

http://www.w3.org/2001/XMLSchema#string

P932

3109926

http://www.w3.org/2001/XMLSchema#string